The Path Forward: Combating COVID-19

Genentech, the American biotechnology company, began trials in March to see if one of its existing medicines could be used to combat COVID-19 as it spread across the U.S. causing hospital overruns and thousands of deaths with a special effort to enroll diverse groups disproportionately impacted by the virus. While setting up these trials, the company changed ways of working to virtually meet the needs of patients who found themselves without access to their medicines and partnered with others to fight the pandemic. Genentech CEO Alexander Hardy believes they’re learning a great deal that they will carry forward to better serve patients in the future. Join Washington Post columnist David Ignatius for a one-on-one conversation with Alexander Hardy on Friday, Nov. 13 at 1:00 p.m. ET.